Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences.

Published
17 hours ago
From
Reuters
Daclatasvir for hepatitis C: added benefit not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that data for patients without cirrhosis of the liver who are infected with hepatitis C virus (HCV) genotype 1, and for patients with HCV genotype 4 are not suitable for proving an added benefit of Daklinza (daclatasvir).

Published
11 December 2014
From
German Institute for Quality and Efficiency in Health Care (IQWiG)
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97%

Published
10 December 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation

An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis

Published
02 December 2014
By
Liz Highleyman
Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use

Regimens containing sofosbuvir (Sovaldi) – including sofosbuvir plus simeprevir (Olysio) – work well for people with hepatitis C genotype 1 in real-world use, which to date has included

Published
02 December 2014
By
Liz Highleyman
FDA declines to approve Bristol-Myers hepatitis drug

Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.

Published
27 November 2014
From
Reuters
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not

Published
27 November 2014
By
Liz Highleyman
"Promising" results in Oxford trials of Hepatitis C vaccine

A new vaccine developed by researchers at the University of Oxford has generated a strong immune response against the Hepatitis C virus in human volunteers. The vaccine is the first Hepatitis C inoculation to reach this stage of clinical trials, and the results have been promising. The 15 healthy human volunteers who took part in the phase 1 safety trial all responded positively.The study found that after the second, booster inoculation, all 15 volunteers had large, broad and sustained T cells responses.

Published
26 November 2014
From
Cherwell
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C

An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for

Published
25 November 2014
By
Liz Highleyman
CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Major regulatory milestone achieved toward approval in the European Union; final decision from the European Commission expected in the first quarter of 2015.

Published
21 November 2014
From
AbbVie press release
← First12345...53Next →

Filter by country